These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19151906)

  • 1. Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine.
    Visch Brink EG; Van Rhee Temme W; Rietveld T; Krulder JW; Van Harskamp F; Van der Cammen TJ
    J Nutr Health Aging; 2009 Jan; 13(1):34-8. PubMed ID: 19151906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
    Weintraub D; Somogyi M; Meng X
    Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
    Farlow MR; Cummings JL; Olin JT; Meng X
    Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):347-52. PubMed ID: 20392862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
    Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
    Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
    Cummings J; Emre M; Aarsland D; Tekin S; Dronamraju N; Lane R
    J Alzheimers Dis; 2010; 20(1):301-11. PubMed ID: 20164585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
    Doraiswamy PM; Krishnan KR; Anand R; Sohn H; Danyluk J; Hartman RD; Veach J
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):705-12. PubMed ID: 12188103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.